Mode
Text Size
Log in / Sign up

AI-driven assessment of ultrawide-field fundus images achieves 85.0% sensitivity for diabetic retinopathy screeningArtificial intelligence helps detect eye damage from diabetes

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that AI-driven screening using ultrawide-field images shows acceptable sensitivity but limited specificity.

This meta-analysis synthesizes the diagnostic performance of artificial intelligence (AI) for identifying diabetic retinopathy (DR) using ultrawide-field fundus images (UWFI). The analysis included 17 studies for the systematic review and 4 studies for the meta-analysis. The primary outcome was the diagnostic performance of AI-driven DR screening using UWFI.

The meta-analysis reported a sensitivity of 85.0% and a specificity of 72.5% for AI-driven DR screening. The area under the receiver operating characteristic curve (AUC) was 0.870 (0.838-0.897). Secondary outcomes included DR stage classification, detection of clinical DR features, and prediction of DR progression, though specific results for these were not detailed in the primary synthesis.

Authors noted several limitations, including a limited number of available studies and the need for larger, more diverse datasets. Furthermore, rigorous external validation across different UWF platforms is required. Clinical application is currently limited by the observed lower specificity compared to sensitivity. These findings should be interpreted with caution due to the limited evidence base.

How this fits prior evidence

This meta-analysis addresses a gap in the technological screening of diabetic retinopathy. While prior coverage noted that DR trials often omit diabetes type and use small samples, this study focuses on the diagnostic accuracy of AI-driven screening. It does not directly relate to the reported risks of dementia, the use of SGLT2 inhibitors for progression, or the efficacy of ranibizumab PDS.

Living with diabetes can put a person's vision at risk. Doctors often look for diabetic retinopathy, a condition where high blood sugar damages the blood vessels in the eyes. Detecting these changes early is vital for protecting a patient's sight.

Researchers looked at 17 different studies to see how artificial intelligence performs when checking wide-view eye images. The AI showed an 85 percent sensitivity rate, meaning it was good at catching cases of the disease. However, its specificity was lower at 72.5 percent, which means it sometimes struggled to correctly identify those without the condition.

While the results are promising, the evidence is still early. The researchers noted that the small number of available studies means we need much larger and more diverse data sets. More testing across different types of imaging platforms is also needed before this technology can be fully relied upon in every clinic.

What this means for you:
AI shows promise in detecting diabetic eye damage but currently has some limits in accurately ruling out the condition.

Common questions

How accurate is AI at finding diabetic retinopathy?

The artificial intelligence showed an 85 percent sensitivity rate when checking wide-field eye images. This means it is quite capable of identifying the disease. However, its specificity was 72.5 percent, which means it is less consistent at correctly identifying patients who do not have the condition.

Is this AI technology ready to replace regular eye exams?

Not yet. While the results are promising, the study notes that the findings should be interpreted with caution. Because there are a limited number of studies available, more large and diverse data sets are needed to confirm how well the technology works across different platforms.

What specific eye issues can this AI detect?

The AI was tested on its ability to identify diabetic retinopathy, distinguish it from other retinal disorders, and classify the stage of the disease. It was also used to look for referable retinal problems and predict how the disease might progress over time.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedNov 2026
View Original Abstract ↓
PURPOSE: Ultrawide-field (UWF) fundus cameras capture a larger retinal area without pupil dilation. The authors summarized evidence and diagnostic performance of artificial intelligence (AI)-driven diabetic retinopathy (DR) assessments using UWF images (UWFIs). METHODS: The authors searched PubMed, Scopus, the Cochrane Library, and Web of Science to February 9, 2025, for studies evaluating DR using UWFIs and AI analyses. They followed the PRISMA guidelines and assessed study quality using the Joanna Briggs Institute Critical Appraisal Checklist for diagnostic accuracy. Forest plots and summary receiver operating characteristic curves estimated sensitivity and specificity of AI-driven DR screening using UWFI. RESULTS: Of 527 records identified, 17 studies were included in the systematic review and four in the meta-analysis. All studies used Optos software. Among the included studies, two evaluated DR discrimination from multiple retinal disorders, six addressed DR stage classification based on guideline scales, six evaluated DR screening, and one each focused on referable retinal pathology detection, DR progression prediction, and detection of clinical DR features. The summary sensitivity, specificity, and area under receiver operating characteristic curve for AI-driven DR screening using UWFI were 85.0%, 72.5%, and 0.870 (0.838-0.897), respectively. UWFI-based AI screening showed acceptable sensitivity but limited specificity. CONCLUSION: AI-driven DR screening using UWFIs may achieve acceptable sensitivity but with limited specificity; however, these findings should be interpreted with caution, given the limited number of available studies. Further studies using larger, diverse data sets with rigorous external validation across UWF platforms are needed to improve generalizability and clarify the clinical role of UWFI-based AI.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.